|
1
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the surveillance, epidemiology, and end results program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhou W, Hao M, Du X, Chen K, Wang G and
Yang J: Advances in targeted therapy for osteosarcoma. Discov Med.
17:301–307. 2014.PubMed/NCBI
|
|
3
|
De Luca A, Carotenuto A, Rachiglio A,
Gallo M, Maiello MR, Aldinucci D, Pinto A and Normanno N: The role
of the EGFR signaling in tumor microenvironment. J Cell Physiol.
214:559–567. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mendelsohn J and Baselga J: Epidermal
growth factor receptor targeting in cancer. Semin Oncol.
33:369–385. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Renoir JM, Marsaud V and Lazennec G:
Estrogen receptor signaling as a target for novel breast cancer
therapeutics. Biochem Pharmacol. 85:449–465. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Siu MK, Abou-Kheir W, Yin JJ, Chang YS,
Barrett B, Suau F, Casey O, Chen WY, Fang L, Hynes P, et al: Loss
of EGFR signaling-regulated miR-203 promotes prostate cancer bone
metastasis and tyrosine kinase inhibitors resistance. Oncotarget.
5:3770–3784. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu L, Wu H, Jiang C, Wang H, Gao B, Yan S,
Qi Y and Zhou S: Dacomitinib, a new pan-EGFR inhibitor, is
effective in killing ovarian cancer cells. Discov Med. 22:297–309.
2016.PubMed/NCBI
|
|
8
|
Do SI, Jung WW, Kim HS and Park YK: The
expression of epidermal growth factor receptor and its downstream
signaling molecules in osteosarcoma. Int J Oncol. 34:797–803.
2009.PubMed/NCBI
|
|
9
|
Lee JA, Ko Y, Kim DH, Lim JS, Kong CB, Cho
WH, Jeon DG, Lee SY and Koh JS: Epidermal growth factor receptor:
Is it a feasible target for the treatment of osteosarcoma? Cancer
Res Treat. 44:202–209. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kersting C, Gebert C, Agelopoulos K,
Schmidt H, van Diest PJ, Juergens H, Winkelmann W, Kevric M,
Gosheger G, Brandt B, et al: Epidermal growth factor receptor
expression in high-grade osteosarcomas is associated with a good
clinical outcome. Clin Cancer Res. 13:2998–3005. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Baxevanis CN, Sotiropoulou PA, Sotiriadou
NN and Papamichail M: Immunobiology of HER-2/neu oncoprotein and
its potential application in cancer immunotherapy. Cancer Immunol
Immunother. 53:166–175. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Abdou AG, Kandil M, Asaad NY, Dawoud MM,
Shahin AA and Eldayem Abd AF: The prognostic role of Ezrin and
HER2/neu expression in osteosarcoma. Appl Immunohistochem Mol
Morphol: AIMM. 24:355–363. 2016. View Article : Google Scholar
|
|
13
|
Yalcin B, Gedikoğlu G, Kutluk T, Varan A,
Akyüz C and Büyükpamukçu M: C-erbB-2 expression and prognostic
significance in osteosarcoma. Pediatric Blood Cancer. 51:222–227.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang Q, Liu F, Wang B, Li Z, Zhou D, Yang
Q, Dong J and Li J: HER-2 expression in biopsy and surgical
specimen on prognosis of osteosarcoma: A systematic review and
meta-analysis of 16 studies. Medicine. 95:e36612016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Akatsuka T, Wada T, Kokai Y, Kawaguchi S,
Isu K, Yamashiro K, Yamashita T, Sawada N, Yamawaki S and Ishii S:
ErbB2 expression is correlated with increased survival of patients
with osteosarcoma. Cancer. 94:1397–1404. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Geller DS and Gorlick R: HER-2 targeted
treatment of osteosarcoma: The challenges of developing targeted
therapy and prognostic factors for rare malignancies. Exp Opin
Pharmacother. 11:51–61. 2010. View Article : Google Scholar
|
|
17
|
Ma J, Lyu H, Huang J and Liu B: Targeting
of erbB3 receptor to overcome resistance in cancer treatment. Mol
Cancer. 13:1052014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hassan SE, Bekarev M, Kim MY, Lin J,
Piperdi S, Gorlick R and Geller DS: Cell surface receptor
expression patterns in osteosarcoma. Cancer. 118:740–749. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hughes DP, Thomas DG, Giordano TJ, Baker
LH and McDonagh KT: Cell surface expression of epidermal growth
factor receptor and Her-2 with nuclear expression of Her-4 in
primary osteosarcoma. Cancer Res. 64:2047–2053. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hua Y, Yang Y and Hughes D: Abstract 197:
Multi-cellular tumor spheroids in vitro model reveals a critical
role of ERBB4 in survival of osteosarcoma. Cancer Res. 71:197.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Enneking WF, Spanier SS and Goodman MA: A
system for the surgical staging of musculoskeletal sarcoma. Clin
Orthop Relat Res. 106–120. 1980.PubMed/NCBI
|
|
22
|
Srirajaskanthan R, Shah T, Watkins J,
Marelli L, Khan K and Caplin ME: Expression of the HER-1–4 family
of receptor tyrosine kinases in neuroendocrine tumours. Oncol Rep.
23:909–915. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu Q, Hao L, Lou Z, Gao X, Gong H, Hong
Y, Fu C and Zhang W: Survival time and prognostic factors of
patients with initial noncurative colorectal liver metastases.
Medicine (Baltimore). 96:e88312017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu H, Sharp GC, Zhao Q, Shirato H and
Jiang SB: Statistical analysis and correlation discovery of tumor
respiratory motion. Phys Med Biol. 52:4761–4774. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nishikawa H, Nishijima N, Arimoto A,
Inuzuka T, Kita R, Kimura T and Osaki Y: Prognostic factors in
patients with hepatitis B virus-related hepatocellular carcinoma
undergoing nucleoside analog antiviral therapy. Oncol Lett.
6:1213–1218. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pahl JH, Ruslan SE, Buddingh EP, Santos
SJ, Szuhai K, Serra M, Gelderblom H, Hogendoorn PC, Egeler RM,
Schilham MW and Lankester AC: Anti-EGFR antibody cetuximab enhances
the cytolytic activity of natural killer cells toward osteosarcoma.
Clin Cancer Res. 18:432–441. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang S, Li C, Armstrong EA, Peet CR,
Saker J, Amler LC, Sliwkowski MX and Harari PM: Dual targeting of
EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR
inhibitors and radiation. Cancer Res. 73:824–833. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang Z, Wang Y, Nayak PS, Dammann CE and
Sanchez-Esteban J: Stretch-induced fetal type II cell
differentiation is mediated via ErbB1-ErbB4 interactions. J Biol
Chem. 287:18091–18102. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Silva SD, Alaoui-Jamali MA, Hier M, Soares
FA, Graner E and Kowalski LP: Cooverexpression of ERBB1 and ERBB4
receptors predicts poor clinical outcome in pN+ oral squamous cell
carcinoma with extranodal spread. Clin Exp Metastasis. 31:307–316.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Anninga JK, van de Vijver MJ,
Cleton-Jansen AM, Kristel PM, Taminiau AH, Nooij M, Egeler RM and
Hogendoorn PC: Overexpression of the HER-2 oncogene does not play a
role in high-grade osteosarcomas. Eur J Cancer. 40:963–970. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Maitra A, Wanzer D, Weinberg AG and Ashfaq
R: Amplification of the HER-2/neu oncogene is uncommon in pediatric
osteosarcomas. Cancer. 92:677–683. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kilpatrick SE, Geisinger KR, King TS,
Sciarrotta J, Ward WG, Gold SH and Bos GD: Clinicopathologic
analysis of HER-2/neu immunoexpression among various histologic
subtypes and grades of osteosarcoma. Mod Pathol. 14:1277–1283.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Scotlandi K, Manara MC, Hattinger CM,
Benini S, Perdichizzi S, Pasello M, Bacci G, Zanella L, Bertoni F,
Picci P and Serra M: Prognostic and therapeutic relevance of HER2
expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer.
41:1349–1361. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yoshida R, Tazawa H, Hashimoto Y, Yano S,
Onishi T, Sasaki T, Shirakawa Y, Kishimoto H, Uno F, Nishizaki M,
et al: Mechanism of resistance to trastuzumab and molecular
sensitization via ADCC activation by exogenous expression of
HER2-extracellular domain in human cancer cells. Cancer Immunol
Immunother. 61:1905–1916. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Long XH, Zhang GM, Peng AF, Luo QF, Zhang
L, Wen HC, Zhou RP, Gao S, Zhou Y and Liu ZL: Lapatinib alters the
malignant phenotype of osteosarcoma cells via downregulation of the
activity of the HER2-PI3K/AKT-FASN axis in vitro. Oncol Rep.
31:328–334. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jullien N, Maudinet A, Leloutre B, Ringe
J, Häupl T and Marie PJ: Downregulation of ErbB3 by Wnt3a
contributes to wnt-induced osteoblast differentiation in
mesenchymal cells. J Cell Biochem. 113:2047–2056. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cai Y, Mohseny AB, Karperien M, Hogendoorn
PC, Zhou G and Cleton-Jansen AM: Inactive Wnt/beta-catenin pathway
in conventional high-grade osteosarcoma. J Pathol. 220:24–33. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xu H, Liu X and Zhao J: Down-regulation of
miR-3928 promoted osteosarcoma growth. Cell Physiol Biochem.
33:1547–1556. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bianchi S, Palli D, Falchetti M, Saieva C,
Masala G, Mancini B, Lupi R, Noviello C, Omerovic J, Paglierani M,
et al: ErbB-receptors expression and survival in breast carcinoma:
A 15-year follow-up study. J Cell Physiol. 206:702–708. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Karamouzis MV, Badra FA and Papavassiliou
AG: Breast cancer: The upgraded role of HER-3 and HER-4. Int J
Biochem Cell Biol. 39:851–856. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Citri A and Yarden Y: EGF-ERBB signalling:
Towards the systems level. Nat Rev Mol Cell Biol. 7:505–516. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Canfield K, Li J, Wilkins OM, Morrison MM,
Ung M, Wells W, Williams CR, Liby KT, Vullhorst D, Buonanno A, et
al: Receptor tyrosine kinase ERBB4 mediates acquired resistance to
ERBB2 inhibitors in breast cancer cells. Cell Cycle. 14:648–655.
2015. View Article : Google Scholar : PubMed/NCBI
|
